La vendita allo scoperto per Evolent Health dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Evolent Health. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Evolent Health (NYSE:EVH) Azioni, Report sulle vendite allo scoperto

Evolent Health

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Evolent Health Inc

EVENT HOSPITALITY & ENTMT by EVENT HOSPITALITY & ENTMT LTD.

EVT Ltd

Morgan Stanley ETF Trust Eaton Vance High Yield ETF

Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and lowers the price target from $35 to $33.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $33

Elevance Health Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)&nbsp;reported on Thursday third-quarter revenues of $44.7 billion, up 5.3% year-over-year, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $43.33 billion</a>.&nbsp;
The increase was driven by higher premium yields in the Health Benefits segment and growth in CarelonRx product revenue, partially offset by membership attrition in&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41379220/elevance-healths-q3-earnings-profit-falls-short-of-expectations-on-higher-medical-costs-issues-soft" rel="noreferrer noopener">the Medicaid business</a>.
The benefit expense ratio was 89.5%, an increase of 270 basis points, driven primarily by the timing mismatch between Medicaid rates and the higher acuity of members.
The company forecasts an adjusted EPS of $33.00, down from the prior guidance of at least $37.20 and the consensus of $37.26.
Evolent Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock is trading lower in reaction to Elevance Health&#8217;s mixed earnings and softer guidance.
Large managed care organizations (MCOs) seem to be facing pressure regarding Medicaid utilization, while outdated data often determine the premiums they receive from states, William Blair noted.
This situation created a disparity between payments and trends in medical expenses following the completion of the redeterminations process. However, this issue is anticipated to be temporary as MCOs collaborate with state partners to recalibrate their pricing.
&#8220;Last, we believe Evolent&#8217;s services remain a compelling value proposition given continued cost pressures facing health plans on Medicare Advantage and Medicaid lines, presenting a compelling growth setup for coming years,&#8221; William Blair analyst wrote.
The analyst indicated Evolent&#8217;s struggles were due to investors anticipating that rising medical costs would impact its at-risk performance suite.
ELV, EVH Price Actions: Elevance Health stock is down 12.12% at $436.64; Evolent Health stock is down 5.54% at $25.05 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41385802/why-is-gamesquare-stock-gaining-today" target="_blank" rel="noreferrer noopener">Why Is GameSquare Stock Gaining Today?</a></li>
</ul>
Photo: Unsplash

Analyst Color

Health Care

Movers

Trading Ideas

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Why Is Elevance Health Stock Trading Lower On Thursday?

Keybanc analyst Matthew Gillmor initiates coverage on Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight rating and announces Price Target of $35.

Initiation

Keybanc Initiates Coverage On Evolent Health with Overweight Rating, Announces Price Target of $35

The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;
<h3>1. Teladoc Health</h3>
Market Cap: $1.4 Billion
Focus Area: Telehealth&nbsp;
Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.
What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.
<h3>2. WELL Health Technologies</h3>
Market Cap: $1.1 Billion
Focus Area: Digital Health Solutions&nbsp;
WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;
WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.
<h3>3. Omnicell</h3>
Market Cap: $1.9 Billion
Focus Area: Automation and analytics
Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.
What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.
<h3>4. IRadimed Corporation&nbsp;</h3>
Market Cap: $700 Million
Focus Area: MRI-Compatible Devices
IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.
With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.
<h3>5. Evolent Health Inc.</h3>
Market Cap: $1.3 Billion
Focus Area: Value-Based Care
Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.
With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.
<h3>6. CareDx, Inc.</h3>
Market Cap: $520 Million
Focus Area: Transplant Diagnostics
CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.
CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.
<h3>7. Tactile Systems Technology, Inc.</h3>
Market Cap: $450 Million
Focus Area: Chronic Disease Management
Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.
Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.
<h4>Conclusion:</h4>
the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Small Cap

CDNA

IRMD

OMCL

TCMD

TDOC

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

In the latest quarter, 7 analysts provided ratings for Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Evolent Health, presenting an average target of $38.29, a high estimate of $45.00, and a low estimate of $31.00. Witnessing a positive shift, the current average has risen by 4.3% from the previous average price target of $36.71.
<img src="https://www.benzinga.com/files/images/story/2024/1728399635_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Evolent Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Evolent Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Evolent Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
<h2>All You Need to Know About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health: Delving into Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Evolent Health displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 37.94%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Evolent Health's net margin excels beyond industry benchmarks, reaching -0.99%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Evolent Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Evolent Health's ROA excels beyond industry benchmarks, reaching -0.25%. This signifies efficient management of assets and strong financial health.
Debt Management: Evolent Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.6.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Evolent Health Through The Eyes Of 7 Analysts

RBC Capital analyst Sean Dodge reiterates Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Outperform and maintains $42 price target.

Reiteration

RBC Capital Reiterates Outperform on Evolent Health, Maintains $42 Price Target

These ten mid-cap stocks were the best performers in August. Are they in your portfolio?
<ol>
<li>Polestar Automotive Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) shares jumped 74.19%. It reported <a href="https://www.benzinga.com//node/40629765" target="_blank" rel="noreferrer noopener">strong second-quarter deliveries</a>.</li>
<li>Upstart Holdings, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) stock escalated 67.32% after the company reported better-than-<a href="https://www.benzinga.com//node/40322490" target="_blank" rel="noreferrer noopener">expected second-quarter results</a>.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares rocketed 58.13%. It reported <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener">mixed second-quarter results</a>.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares rose 52.46%. The company reported a better-than-consensus <a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">second-quarter loss per share</a>.</li>
<li>Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) stock gained 51.17%. The stock got a boost from investments by Google<a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener"> and </a><a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener">SoftBank Group Corp</a><a href="https://www.benzinga.com//node/40419923" target="_blank" rel="noreferrer noopener"> (OTCPK: SFTBF)</a>.</li>
<li>Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) shares were up 46.81%. It reported <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener">better-than-expected quarterly results</a>.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock jumped 42.89%. The company issued upbeat guidance for 2024 and 2025 and better-than-<a href="https://www.benzinga.com//node/40288203" target="_blank" rel="noreferrer noopener">expected second-quarter earnings</a>.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) shares escalated 42.51%. The company initiated an auction process after receiving takeover inquiries from private<a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener"> equity firms and healthcare providers</a>.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) stock rose 42.23%. It reported a <a href="https://www.benzinga.com//node/40587744" target="_blank" rel="noreferrer noopener">second-quarter earnings beat</a>.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares grew 42.07%. The company announced that it&#8217;s on track to launch five <a href="https://www.benzinga.com//node/40398813" target="_blank" rel="noreferrer noopener">satellites in early September</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40764288/affirm-shopify-and-starbucks-were-among-top-10-large-cap-best-performers-for-august-are-the-others" target="_blank" rel="noreferrer noopener">Affirm, Shopify And Starbucks Were Among Top 10 Large Cap Best Performers For August: Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40764325/intel-moderna-and-dollar-general-were-among-top-10-large-cap-losers-in-august-are-the-others-in-yo" target="_blank" rel="noreferrer noopener">Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Company

Asia

Mid Cap

ASTS

IOVA

LUMN

PSNY

SFTBF

SMTC

UPST

AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and maintains $33 price target.

Truist Securities Maintains Buy on Evolent Health, Maintains $33 Price Target

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares soared 32.91%. The company announced that Lucid Financial Services has added leasing to its range of <a href="https://www.benzinga.com//node/40466130" target="_blank" rel="noreferrer noopener">financing options in Canada</a>. Fed Chair Powell&#8217;s comments about the economy and interest rate cuts also improved the sentiment.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock rose 32.04% after it reported second-<a href="https://www.benzinga.com//node/40487035" target="_blank" rel="noreferrer noopener">quarter financial results</a>.</li>
<li>PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) shares escalated 22.67% after the company announced FDA 510(k) clearance of <a href="https://www.benzinga.com//node/40481411" target="_blank" rel="noreferrer noopener">its HYDROS Robotic system</a>.</li>
<li>Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) shares were up 20.02%.</li>
<li>Evolent Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) stock upped 19.98% following a report suggesting <a href="https://www.benzinga.com//node/40529349" target="_blank" rel="noreferrer noopener">the company is exploring a sale</a>.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares jumped 19.50% following a report suggesting that Brookfield Asset Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) is seeking debt financing to acquire the company.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) stock increased 19.33%.</li>
<li>Amer Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) stock escalated 16.60% after it reported better-than-expected second-quarter <a href="https://www.benzinga.com//node/40466836" target="_blank" rel="noreferrer noopener">results and raised its FY24 EPS outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543876/zoom-video-microstrategy-and-target-were-among-top-11-large-cap-gainers-last-week-aug-18-aug-24-ar" target="_blank" rel="noreferrer noopener">Zoom Video, MicroStrategy And Target Were Among Top 11 Large Cap Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40543907/snowflake-jd-com-and-temu-parent-pdd-are-among-top-8-large-cap-losers-last-week-aug-18-aug-24-are-" target="_blank" rel="noreferrer noopener">Snowflake, JD.com And Temu Parent PDD Are Among Top 8 Large Cap Losers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

CRDO

GRFS

LCID

NUVL

PRCT

Lucid, Grifols And Amer Sports Are Among Top 8 Mid Cap Stock Gainers Last Week (Aug 18-Aug 24): Are The Others In Your Portfolio?

Evolent Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) is reportedly <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">up for sale</a>. 
What Happened: The Arlington, Virginia-based software provide initiated an auction process after receiving takeover inquiries from private equity firms and healthcare providers. 
Among the potential suitors are private equity giants TPG Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), Clayton, Dubilier &amp; Rice (CD&amp;R), and KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>). Notably, TPG was one of Evolent's early investors.
Reuters noted that health insurer Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) has also expressed interest and may join forces with a private equity partner to pursue a deal.
Founded in 2011, Evolent offers software solutions to help healthcare providers and insurers transition from fee-for-service to value-based care models. The company partners with prominent industry players like Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>).
Why It Matters: Evolent has seen financial challenges despite a 38% revenue increase in its latest quarter. The company struggled with lower billing rates from payer customers, leading to results below market expectations.
Its history of attracting acquisition interest includes a 2021 Bloomberg <a href="https://www.bloomberg.com/news/articles/2021-09-29/walgreens-said-to-weigh-takeover-of-evolent-health" target="_blank" rel="noreferrer noopener">report</a> that Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) was considering a deal.
Activist investor Engaged Capital took a significant stake in Evolent in 2020 and pushed for changes to enhance shareholder value.
Price Action: EVH stock is up 0.62% at $32.30 during the premarket session at last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40526625/astrazeneca-threatens-to-move-vaccine-production-amid-reduced-state-support" target="_blank" rel="noreferrer noopener">AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support</a>.</li>
</ul>

Rumors

Evolent Health Explores Sale, Garners Inbound Interest From Private Equity Firms

WIIM

Evolent Health shares are trading higher following a report suggesting that the company is exploring a sale.

Evolent Health Explores Sale Following Acquisition Interest; Potential Bidders Include TPG, CD&R, KKR, And Elevance Health

In the latest quarter, 4 analysts provided ratings for Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Evolent Health, revealing an average target of $37.75, a high estimate of $45.00, and a low estimate of $31.00. Marking an increase of 7.86%, the current average surpasses the previous average price target of $35.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1724072411_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Evolent Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Evolent Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evolent Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evolent Health analyst ratings.</a>
<h2>About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Breaking Down Evolent Health's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Evolent Health showcased positive performance, achieving a revenue growth rate of 37.94% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Evolent Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Evolent Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Evolent Health's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.25%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.6.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About Evolent Health

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and raises the price target from $36 to $45.

JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $45

U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday.
Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) rose sharply during Friday's session after the company reported<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40288024/expedias-q2-triumph-analysts-highlight-vrbo-as-bright-spot-praise-growth-in-busines"> better-than-expected second-quarter financial results.</a>
Expedia Group reported quarterly earnings of $3.51 per share which beat the analyst consensus estimate of $3.06 per share. The company reported quarterly sales of $3.558 billion which beat the analyst consensus estimate of $3.534 billion.
Expedia Group shares jumped 9.4% to $129.02 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) gained 32% to $3.55 after the company reported better-than-expected second-quarter financial results. Also, William Blair upgraded the stock from Market Perform to Outperform.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) gained 31.6% to $33.82 after the company reported better-than-expected first-quarter financial results. Additionally, the company issued FY24 revenue guidance above estimates.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) shares surged 29.5% to $15.80 after the company reported better-than-expected second-quarter financial results and raised its FY24 and FY25 revenue guidance above estimates.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) climbed 26.2% to $33.13 after the company reported better-than-expected second-quarter revenue results.</li>
<li>Evolent Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) rose 24.2% to $25.92 after the company reported better-than-expected quarterly financial results. Also, Truist Securities upgraded the stock from Hold to Buy and raised its price target from $28 to $33.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 20.2% to $9.54 after the company reported better-than-expected second-quarter financial results and issued third-quarter product revenue guidance above estimates.</li>
<li>CarGurus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) gained 18.2% to $26.48 after the company reported better-than-expected second-quarter financial results and issued third-quarter non-GAAP EPS guidance above estimates.</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) gained 15.6% to $4.2550 after the company reported better-than-expected second-quarter financial results.</li>
<li>Genpact Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>) rose 14.9% to $37.23 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates. Also, the company raised its FY24 EPS guidance above estimates.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) climbed 13.7% to $22.19 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>DigitalOcean Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) rose 13.4% to $32.99 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 12.2% to $5.35 after the company reported better-than-expected second-quarter financial results. Also, the company announced it hot fired its new rocket engine Archimedes for the first time.</li>
<li>Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) rose 11.3% to $101.91 after the company reported better-than-expected second-quarter financial results.</li>
<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) gained 10.6% to $46.31.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) rose 9.6% to $96.81 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates. Also, Keybanc and Susquehanna raised their respective price targets on the stock.</li>
<li>DXC Technology Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) climbed 7.2% to $19.64 after the company reported better-than-expected quarterly financial results..</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) gained 5.8% to $894.83.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40278354/top-2-risk-off-stocks-that-may-implode-in-august">Top 2 Risk Off Stocks That May Implode In August</a></li>
</ul>

Intraday Update

Markets

ADMA

AKAM

BLND

CARG

DOCN

DOCS

EXPE

RKLB

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday

Evolent Health shares are trading higher after the company reported better-than-expected Q2 financial results. Also, Truist Securities upgraded the stock from Hold to Buy and raised its price target from $28 to $33.

JMP Securities analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and lowers the price target from $34 to $31.

JMP Securities Maintains Market Outperform on Evolent Health, Lowers Price Target to $31

Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) from Hold to Buy and raises the price target from $28 to $33.

Upgrades

Truist Securities Upgrades Evolent Health to Buy, Raises Price Target to $33

Evolent Health shares are trading higher after the company reported better-than-expected Q2 financial results.

Evolent Health dips on report Elevance dropped out of bidding

JMP Securities analyst Constantine Davides has maintained their bullish stance on EVH stock, giving a Buy rating on August 27. Constantine Davides ...

Evolent Health Buy Rating Affirmed with Increased Price Target Amid Growth Prospects and M&A Speculation

Guggenheim SMid Cap Value Fund Q2 2024 Commentary

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exact Sciences (EXAS – Research Report), AdaptHealth...

Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), AdaptHealth (AHCO)

Barclays analyst Stephanie Davis maintained a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $39.00. The comp...

Barclays Sticks to Its Buy Rating for Evolent Health (EVH)

TD Cowen analyst Charles Rhyee maintained a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $63.00. The compan...

TD Cowen Sticks to Their Buy Rating for Evolent Health (EVH)

In a report released today, Sean Dodge from RBC Capital maintained a Buy rating on Evolent Health (EVH – Research Report), with a price target of $...

RBC Capital Remains a Buy on Evolent Health (EVH)

What's next for health insurers as Medicare finalizes 2025 Star Ratings?

In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on Evolent Health (EVH – Research Report), with a price target of $...

TD Cowen Reaffirms Their Buy Rating on Evolent Health (EVH)

Citi lowered the firm's price target on Evolent Health (EVH) to $33 from $35 and keeps a Buy rating on the shares as part of a Q3 earnings preview....

Comments

Evolent Health

Vendite allo scoperto

Evolent Health (NYSE:EVH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO